Status:
TERMINATED
Carotid B-mode Ultrasound Study to Compare Anti-Atherosclerotic Effect of Torcetrapib/Atorvastatin to Atorvastatin.
Lead Sponsor:
Pfizer
Conditions:
Mixed Hyperlipidemia
Eligibility:
All Genders
18-70 years
Phase:
PHASE3
Brief Summary
The Torcetrapib project was terminated on December 2, 2006 due to safety findings. To look at ultrasound images taken in the carotid arteries and to look at various lipids in the blood of people with...
Detailed Description
For additional information please call: 1-800-718-1021
Eligibility Criteria
Inclusion
- Diagnosis of mixed hyperlipidemia
- At least 18 years of age
Exclusion
- Women who are pregnant or lactating, or planning to become pregnant.
- Subjects with a clinically indicated need for statin (HMG-CoA reductase inhibitor) therapy other than atorvastatin or other concomitant therapy with known lipid altering effects on LDL-C and HDL-C including fibrates and nicotinic acid (high doses)
- Subjects taking any drugs known to be associated with an increased risk of myositis in combination with HMG-CoA reductase inhibitors
- Subjects with any other medical condition or laboratory abnormality which could affect subject safety, preclude evaluationof response, or render unlikely that the subject would complete the study
Key Trial Info
Start Date :
November 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2006
Estimated Enrollment :
755 Patients enrolled
Trial Details
Trial ID
NCT00134238
Start Date
November 1 2003
End Date
December 1 2006
Last Update
February 17 2012
Active Locations (51)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Gilbert, Arizona, United States
2
Pfizer Investigational Site
Phoenix, Arizona, United States
3
Pfizer Investigational Site
Scottsdale, Arizona, United States
4
Pfizer Investigational Site
Alhambra, California, United States